Montreal, May 6, 2026 – Researchers from McGill University have introduced a groundbreaking new class of molecules that could significantly reshape drug discovery and development. The technology, called Aptamer‑Like ENcoded OligoMERs (Alenomers), combines the advantages of antibodies and DNA‑based therapeutics while overcoming key limitations of both.